TMEM165: A Potential Drug Target and Biomarker (G55858)

Target Name: TMEM165

NCBI ID: G55858

TMEM165

TMEM165: A Potential Drug Target and Biomarker

TMEM165 (Tissue Membrane Expl anchor 165) is a protein that is expressed in various tissues and cell types in the body. It is a member of the superfamily of transmembrane protein (SMP) family and is involved in several cellular processes, including cell signaling, cell adhesion, and tissue structure.

TMEM165 has been identified as a potential drug target and has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its function as a drug target makes it an attractive target for researchers to study and develop new treatments.

One of the key challenges in studying TMEM165 as a drug target is its complex structure. TMEM165 is a transmembrane protein that spans the cell membrane and is involved in multiple cellular processes. It consists of an extracellular region, a transmembrane region, and an intracellular region . The transmembrane region of TMEM165 is made up of a伪尾尾 structure and is responsible for its unique structure and function.

The 伪尾尾 structure of TMEM165 is composed of two transmembrane伪 helices and two transmembrane尾 helices. The 伪尾尾 helix is 鈥嬧?媋 type of secondary structure that is characterized by a repeating pattern of amino acids that are turned around a central axis. The 尾 helices are similar to the 伪 helices but are shorter and more compact. The 尾 helices are responsible for the protein's unique 3D structure and for its ability to interact with other proteins.

TMEM165 has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that high levels of TMEM165 are associated with poor prognosis in neuroblastoma, a type of cancer that affects children. Additionally , TMEM165 has been shown to be involved in several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its role in disease, TMEM165 has also been shown to be a potential drug target. Studies have shown that TMEM165 can be targeted by small molecules and can be inhibited by these molecules, which could lead to new treatments for these diseases. For For example, research has shown that inhibiting TMEM165 with small molecules can lead to a reduction in neuroblastoma cell proliferation and survival.

TMEM165 is also a potential biomarker for several diseases. Its expression has been shown to be elevated in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that TMEM165 may be a useful biomarker for these diseases and could be used to diagnose and monitor the progression of these conditions.

In conclusion, TMEM165 is a protein that is involved in several cellular processes and has been identified as a potential drug target and biomarker. Further research is needed to fully understand its function and potential as a drug target and biomarker.Studies are also needed to determine the best way to target TMEM165 and to develop new treatments for diseases associated with its high expression.

Protein Name: Transmembrane Protein 165

Functions: May function as a calcium/proton transporter involved in calcium and in lysosomal pH homeostasis. Therefore, it may play an indirect role in protein glycosylation

The "TMEM165 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM165 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets